XCUR
Exicure, Inc.6.06
+0.33+5.76%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
38.63MP/E (TTM)
-Basic EPS (TTM)
-3.72Dividend Yield
0%Recent Filings
8-K
10-Q
8-K
8-K
Board adds two, loses four
Exicure's board reshaped on September 8, 2025, with Sangjn Yeo and Aejin Hwang appointed as Class II directors, filling two seats while four others—Ho Jung John, Chang Keun Choi, Sangwook Song, and Minwoo Kang—resigned without disagreements. Yeo chairs the audit committee, joined by Hwang; each earns a $20,000 annual retainer. Four vacancies remain. This shift bolsters governance oversight amid biotech transitions.
8-K
Exicure's Q2 loss widens
Exicure reported a $2.6 million net loss for Q2 2025, up from $0.6 million last year, driven by $0.9 million in new R&D expenses after acquiring GPCR USA, which boosted G&A by $0.3 million too. Cash dwindled to $7.9 million from $12.5 million at year-end, signaling tight finances. Substantial funding is urgently needed. Operations burn fast now.
CPMV
Mosaic ImmunoEngineering Inc.
0.40+0.00
CURX
Curanex Pharmaceuticals Inc
0.41-0.02
EPIX
ESSA Pharma Inc.
0.20+0.00
EXOZ
eXoZymes Inc.
12.52-1.78
NBY
NovaBay Pharmaceuticals, Inc.
3.16+0.45
OKUR
OnKure Therapeutics, Inc.
3.02-0.18
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18
XBIT
XBiotech Inc.
2.45-0.08
YDES
YD Bio Limited
12.62+0.22